Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

Eczema Treatments in Development

An overview of potential new medications and therapies

Drug Approval Phases

Before a drug is approved, it must go through rigorous testing to determine if it is safe and effective.

  • Pre-Clinical: The drug is tested in animals to get an idea of how it may work in humans.
  • Phase I: The drug is tested in a small group of people usually without eczema to better understand the mechanism of action, general safety and if there are side effects.
  • Phase II: The drug is tested on a larger group of people who have eczema to see how the drug works and if it is safe.
  • Phase III: The drug is tested in even more people with eczema to further assess effectiveness, safety and side effects.
  • FDA Approved: FDA deems the drug is effective and safe for treating eczema.

From the laboratory to your medicine cabinet — the process of researching and developing a drug is long, complicated and costly. It takes an average of 10 years and more than $2 billion to bring new medications and therapies to market. Less than 15% of all the drugs in development make it through to patients.

The idea for a potential new treatment typically begins from basic science research. Basic science an area of medical research that seeks to understand broadly how and why our bodies do what they do, and how and why a disease such as eczema starts, develops and evolves.

From these findings, scientists may identify a compound (early stage drug) that they believe will help stop a particular symptom or symptoms of a disease. This begins the pre-clinical stage of drug development whereby researchers look at how the drug may work in the body (mechanism of action), dosage, side effects, and effectiveness of the drug. Not all compounds begin from basic research, scientists may get ideas through looking at existing drugs that have unintended effects and results from new technologies, among others.

If the findings from this pre-clinical research offer promising data on the compound, scientists then move into phase I of clinical trials. In order to begin clinical trials, researchers must apply to the Food and Drug Administration (FDA) to show that the study meets minimum FDA research requirements.

Depending on the outcomes of the prior phase of research, the study moves to the next phase of the clinical trial process, testing the compound on larger and more diverse groups of people. In each phase, researchers are gathering information on how safe and effective the drug is for its potential use.

At the end of phase III, researchers file a New Drug Application (NDA) with the FDA. The NDA compiles all the research done on the drug to date for the FDA to review. From this NDA, the FDA either approves the treatment for widespread use, denies the drug, or requests additional information in order to make an informed decision.

Filters

By Class
By Phase

injectables

AQX-1125

details
  • AQX-1125
  • Class: Injectables
  • Sponsor: Aquinox Pharmaceuticals, Inc.
  • Mechanism: Activates SHIP1 pathway
pre-clinical
phase I
phase II
phase III
FDA approved

Bacille Calmette Guerin (BCG) vaccine at birth

details
  • Bacille Calmette Guerin (BCG) vaccine at birth
  • Class: Injectables
  • Sponsor: Murdoch Childrens Research Institute
  • Mechanism:
pre-clinical
phase I
phase II
phase III
FDA approved

BMS-981164

details
  • BMS-981164
  • Class: Injectables
  • Sponsor: Bristol-Myers Squibb
  • Mechanism: biologic (anti-IL31 monoclonal antibody)
pre-clinical
phase I
phase II
phase III
FDA approved

CIM331

details
  • CIM331
  • Class: Injectables
  • Sponsor: Chugai Pharmaceutical
  • Mechanism: Anti-IL-31 receptor
pre-clinical
phase I
phase II
phase III
FDA approved

CNTO 7160

details
  • CNTO 7160
  • Class: Injectables
  • Sponsor: Janssen Research & Development, LLC
  • Mechanism:
pre-clinical
phase I
phase II
phase III
FDA approved

Dupilumab efficacy and safety in pediatric patients with AD >6 and <18 years

details
  • Dupilumab efficacy and safety in pediatric patients with AD >6 and <18 years
  • Class: Injectables
  • Sponsor: Regeneron Pharmaceuticals
  • Mechanism: biologic IL-4R Antibody
pre-clinical
phase I
phase II
phase III
FDA approved

Furestem-AD

details
  • Furestem-AD
  • Class: Injectables
  • Sponsor: Kang Stem Biotech Co., Ltd.
  • Mechanism: Mesenchymal stem cells
pre-clinical
phase I
phase II
phase III
FDA approved

ILV-094

details
  • ILV-094
  • Class: Injectables
  • Sponsor: Rockefeller University
  • Mechanism: anti IL-22
pre-clinical
phase I
phase II
phase III
FDA approved

Lebrikizumab

details
  • Lebrikizumab
  • Class: Injectables
  • Sponsor: Hoffman-La Roche
  • Mechanism: anti-IL13
pre-clinical
phase I
phase II
phase III
FDA approved

MEDI9929

details
  • MEDI9929
  • Class: Injectables
  • Sponsor: Medimmune LLC; Amgen
  • Mechanism: Antibody that blocks interaction of thymic stromal lymphopoietin (TSLP) with the TSLP receptor
pre-clinical
phase I
phase II
phase III
FDA approved

Nemolizumab

details
  • Nemolizumab
  • Class: Injectables
  • Sponsor: Galderma R&D
  • Mechanism: biologic IL-31 Antibody
pre-clinical
phase I
phase II
phase III
FDA approved

Secukinumab

details
  • Secukinumab
  • Class: Injectables
  • Sponsor: Icahn School of Medicine at Mount Sinai; Novartis
  • Mechanism: Antibody that binds to and neutralizes proinflammatory cytokine interleukin 17A (IL-17A)
pre-clinical
phase I
phase II
phase III
FDA approved

Tralokinumab

details
  • Tralokinumab
  • Class: Injectables
  • Sponsor: Medimmune LLC
  • Mechanism: anti-IL13
pre-clinical
phase I
phase II
phase III
FDA approved

Ustekinumab

details
  • Ustekinumab
  • Class: Injectables
  • Sponsor: Rockefeller University
  • Mechanism: anti-IL12/23
pre-clinical
phase I
phase II
phase III
FDA approved

XmAb 7195

details
  • XmAb 7195
  • Class: Injectables
  • Sponsor: Xencor
  • Mechanism: biologic
pre-clinical
phase I
phase II
phase III
FDA approved

orals

Apremilast (CC-10004)

details
  • Apremilast (CC-10004)
  • Class: Orals
  • Sponsor: Celgene Corporation
  • Mechanism: PDE-4 inhibitor
pre-clinical
phase I
phase II
phase III
FDA approved

Asimadoline

details
  • Asimadoline
  • Class: Orals
  • Sponsor: Tioga Pharmaceuticals
  • Mechanism: Selective kappa-opoid receptor agonist
pre-clinical
phase I
phase II
phase III
FDA approved

Baricitinib (LY3009104)

details
  • Baricitinib (LY3009104)
  • Class: Orals
  • Sponsor: Eli Lilly and Company
  • Mechanism: JAK 1 and JAK 2 Inhibitor
pre-clinical
phase I
phase II
phase III
FDA approved

DS107G

details
  • DS107G
  • Class: Orals
  • Sponsor: Dignity Sciences, LTD
  • Mechanism: Derivative of an omega-6 fatty acid
pre-clinical
phase I
phase II
phase III
FDA approved

Ganoderma Tea

details
  • Ganoderma Tea
  • Class: Orals
  • Sponsor: Hong Kong Baptist University
  • Mechanism:
pre-clinical
phase I
phase II
phase III
FDA approved

KHK4577

details
  • KHK4577
  • Class: Orals
  • Sponsor: Kyowa Hakko Kirin Company, Limited
  • Mechanism: Interventional
pre-clinical
phase I
phase II
phase III
FDA approved

KM110329

details
  • KM110329
  • Class: Orals
  • Sponsor: Kyunghee University Medical Center
  • Mechanism: Dietary supplement
pre-clinical
phase I
phase II
phase III
FDA approved

Oc000459

details
  • Oc000459
  • Class: Orals
  • Sponsor: Atopix Therapeutics, Ltd.
  • Mechanism: DP2 antagonist
pre-clinical
phase I
phase II
phase III
FDA approved

QAW039

details
  • QAW039
  • Class: Orals
  • Sponsor: Novartis Pharmaceuticals
  • Mechanism: (PGD2), DP2 (CRTH2)
pre-clinical
phase I
phase II
phase III
FDA approved

Trimethoprim/sulfamethoxazole vs Cephalaxin vs Doxycycline vs Sodium Hypochlorite

details
  • Trimethoprim/sulfamethoxazole vs Cephalaxin vs Doxycycline vs Sodium Hypochlorite
  • Class: Orals
  • Sponsor: National Cancer Institute (NCI)
  • Mechanism: Effects on treatments on Atopic Dermatitis. Characterizing microbiome alterations with drugs in column 1
pre-clinical
phase I
phase II
phase III
FDA approved

VLY-686

details
  • VLY-686
  • Class: Orals
  • Sponsor: Vanda Pharmaceuticals
  • Mechanism: anti-pruritic
pre-clinical
phase I
phase II
phase III
FDA approved

VPD-737 for Prurigo Nodularis

details
  • VPD-737 for Prurigo Nodularis
  • Class: Orals
  • Sponsor: Menlo Therapeutics Inc
  • Mechanism: Neurokinin-1 (NK1) Receptor Antagonist
pre-clinical
phase I
phase II
phase III
FDA approved

ZPL-3893787

details
  • ZPL-3893787
  • Class: Orals
  • Sponsor: Ziarco Pharma Ltd
  • Mechanism: Histamine H4 receptor antagonist
pre-clinical
phase I
phase II
phase III
FDA approved

topicals

AM1030 Cream

details
  • AM1030 Cream
  • Class: Topicals
  • Sponsor: AnaMar AB
  • Mechanism: 5-HT2B receptor antagonist
pre-clinical
phase I
phase II
phase III
FDA approved

Amino Acid Moisturizing Cream/Desonide Cream

details
  • Amino Acid Moisturizing Cream/Desonide Cream
  • Class: Topicals
  • Sponsor: NeoStrata Company, Inc.
  • Mechanism: hydrates skin/anti-inflammatory
pre-clinical
phase I
phase II
phase III
FDA approved

Clemastine Fumarate + Dexamethasone

details
  • Clemastine Fumarate + Dexamethasone
  • Class: Topicals
  • Sponsor: EMS
  • Mechanism: anti-inflammatory
pre-clinical
phase I
phase II
phase III
FDA approved

CT327

details
  • CT327
  • Class: Topicals
  • Sponsor: Creabilis SA
  • Mechanism: Anti-Pruritic
pre-clinical
phase I
phase II
phase III
FDA approved

DSXS (Desoximetasone Topical)

details
  • DSXS (Desoximetasone Topical)
  • Class: Topicals
  • Sponsor: Taro Pharmaceuticals
  • Mechanism:
pre-clinical
phase I
phase II
phase III
FDA approved

E6005

details
  • E6005
  • Class: Topicals
  • Sponsor: Eisai Co., Ltd.
  • Mechanism: PDE4 Inhibitor
pre-clinical
phase I
phase II
phase III
FDA approved

GSK2894512 Cream

details
  • GSK2894512 Cream
  • Class: Topicals
  • Sponsor: GlaxoSmithKline
  • Mechanism: Non-stereoidal anti-inflammatory
pre-clinical
phase I
phase II
phase III
FDA approved

Holly Mangrove Shower Gel

details
  • Holly Mangrove Shower Gel
  • Class: Topicals
  • Sponsor: Mahidol University
  • Mechanism: Improves skin barrier function
pre-clinical
phase I
phase II
phase III
FDA approved

LEO 32731

details
  • LEO 32731
  • Class: Topicals
  • Sponsor: LEO Pharma
  • Mechanism: inhibits secretion of TNF-a, IFN-a, IFN-y, and IL-5 but increases anti-inflammatory IL-10.
pre-clinical
phase I
phase II
phase III
FDA approved

Moisturizer + Subjects Own Antimicrobial Bacteria

details
  • Moisturizer + Subjects Own Antimicrobial Bacteria
  • Class: Topicals
  • Sponsor: Richard Gallo, University of California, San Diego
  • Mechanism: Decrease S. aureus colonization and increase colonization by protective Staph species
pre-clinical
phase I
phase II
phase III
FDA approved

MRX-6 Cream 2%

details
  • MRX-6 Cream 2%
  • Class: Topicals
  • Sponsor: Celsus Therapeutics PLC
  • Mechanism: Anti-inflammatory
pre-clinical
phase I
phase II
phase III
FDA approved

Omiganan (CLS001)

details
  • Omiganan (CLS001)
  • Class: Topicals
  • Sponsor: Cutanea Life Sciences, Inc.
  • Mechanism: Cationic antimicrobial peptide
pre-clinical
phase I
phase II
phase III
FDA approved

OPA-15406

details
  • OPA-15406
  • Class: Topicals
  • Sponsor: Otsuka Pharmaceutical Co., Ltd.
  • Mechanism: PDE-4 inhibitor
pre-clinical
phase I
phase II
phase III
FDA approved

Q301

details
  • Q301
  • Class: Topicals
  • Sponsor: Qurient Co., Ltd
  • Mechanism: anti-inflammatory
pre-clinical
phase I
phase II
phase III
FDA approved

SB011

details
  • SB011
  • Class: Topicals
  • Sponsor: Sterna Biologics GmbH & Co. KG
  • Mechanism: Cleaves GATA-3 mRNA
pre-clinical
phase I
phase II
phase III
FDA approved

Sodium Hypochlorite Solution

details
  • Sodium Hypochlorite Solution
  • Class: Topicals
  • Sponsor: Makati Medical Center
  • Mechanism: antimicrobial
pre-clinical
phase I
phase II
phase III
FDA approved

other

Immunoadsportions with an IgE-Specific Adsorption Column

details
  • Immunoadsportions with an IgE-Specific Adsorption Column
  • Class: Other
  • Sponsor: Universitaire Ziekenhuizen Leuven
  • Mechanism: Removal of IgE after apheresis of blood
pre-clinical
phase I
phase II
phase III
FDA approved